ALK and renal cell carcinoma: Notably, the 2022 WHO “Blue Book” update is the first to designate molecularly defined renal tumors, such as TFEB-altered RCC, ALK-rearranged RCC, and ELOC-mutated RCC, which cannot be diagnosed solely by assessment of tumor morphology.